Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
7,173.91
(
0.12%
)
US TECH 100
26,555.65
(
0.00%
)
Dow Jones
49,310.32
(
0.00%
)
Brent Oil
102.12
(
0.58%
)
Bitcoin
76,935.00
(
-2.19%
)
News Focus
News Focus
Post# of 3757
Next 10
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

go seek

Send PM Follow Ignore
Followers 23
Posts 5149
Boards Moderated 0
Alias Born 06/24/2006

go seek

Re: Jonathan Robinson post# 1052

Tuesday, 05/15/2007 6:12:01 PM

Tuesday, May 15, 2007 6:12:01 PM

Post# of 3757
Thank you Jon... nice to see a positive trend (for a change : )

TYZEKA is significantly better than Hepsera. An analysis of clinical data shows this.

1Q07 Hepsera sales were $71.3M ($285M annualized), +35% year-over-year, +8% quarter-over-quarter.
http://www.investorshub.com/boards/read_msg.asp?message_id=18908687

Idenix has a quality HBV product... and this product may be enhanced //..\\ by valtorcitabine and nucleotides
http://www.investorshub.com/boards/read_msg.asp?message_id=18910784






The creation of a thousand forests is in one acorn.

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote